Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF(V600E) Mutated Papillary Thyroid Cancer: Two Case Reports

Background: A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to ach...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thyroid
Main Authors: White, Paul S., Pudusseri, Anita, Lee, Stephanie L., Eton, Omar
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2017
Assuntos:
Case Studies, and Patients with Remarkable Features or Rare Disorders
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6874808/
https://ncbi.nlm.nih.gov/pubmed/28805135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2017.0106
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados